HARROW HEALTH INC HROW 深 滬
等待開盤 08-08 09:30:00 美东时间
32.64
-0.380
-1.15%
華盛通- 最 高33.55
- 今 開33.10
- 成交量 18.29万股
- 最 低 32.505
- 昨 收 33.02
- 總市值 11.98亿
- 52周最高 59.23
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 20.85
- 委 比 -20.00%
- 總股本 3669.96万
- 歷史最高 59.23
- 量 比 0.62
- 振 幅 3.16%
- 歷史最低 3.33
- 每 手 1
- 風險率 13.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference
Harrow, a leading North American eyecare pharmaceutical company, announced that its CEO, Mark L. Baum, and CFO, Andrew Boll, will participate in H.C. Wainwright’s 5th Annual Ophthalmology Conference on August 13, 2025. Mark will join a fireside chat at 8:30 a.m. ET and participate in a panel discussion on “Novel Treatments for Front-of-the-Eye Indications” at 1 p.m. ET. Both sessions will be webcast live and available on Harrow’s website for 90 d...
08-06 11:00
Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025
Harrow Inc. will announce its Q2 2025 financial results on August 11, 2025, after market close. A conference call and live webcast to discuss the results will be held on August 12, 2025, at 8:00 a.m. Eastern Time. The webcast and call registration details are available on the company’s website. Harrow, a leading North American eyecare pharmaceutical company, focuses on developing innovative ophthalmic products. For more information, visit harrow....
07-29 11:00
Cantor Fitzgerald Initiates Coverage On Harrow with Overweight Rating, Announces Price Target of $76
Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Harrow (NASDAQ:HROW) with a Overweight rating and announces Price Target of $76.
07-11 19:59
William Blair Bullish On Harrow's High-Margin Branded Eye Drug Strategy
Harrow licensed U.S. rights to FDA-approved BYQLOVI for post-surgical eye pain and adds momentum to its branded ophthalmic drug strategy.
06-12 00:58
Assessing Harrow: Insights From 4 Financial Analysts
Harrow (NASDAQ:HROW) has been analyzed by 4 analysts in the last three months, ...
06-10 21:00
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals
TAIPEI, June 9, 2025 /PRNewswire/ -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW), today anno...
06-09 19:00
Jim Cramer Is 'OK' With Harrow, Recommends Buying This Energy Stock
Jim Cramer takes a look at Harrow, Pfizer, Kinsale Capital, Manulife Financial, Iron Mountain and more on "Mad Money."
05-13 21:09
美股大行评级 | 潜在涨幅455.56%！Medicus Pharma获D. Boral Capital升目标价至27美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1128971739548127232.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• D. Boral Capital：维持Medicus Pharma(MDCX)"买入"评级，目标价从14美元升至27美元</p> <p>• 蒙特利尔银行：维持Disc Medicine(IRON)"跑赢大市"评级，目标价从
05-13 08:50
HC Wainwright & Co. Maintains Buy on Harrow, Raises Price Target to $60
HC Wainwright & Co. analyst Yi Chen maintains Harrow (NASDAQ:HROW) with a Buy and raises the price target from $57 to $60.
05-12 19:08
Harrow FY2025 Revenue Outlook Of $280.00M+ Vs $283.19M Est
Path to 2025 Revenue Guidance: More than $280 MillionI remain confident in our 2025 revenue expectations and guidance of over $280 million. Revenues areexpected to accelerate quarter-over-quarter, and we see this
05-09 04:46
